LB Pharmaceuticals Inc balance sheet LBRX

As of Sep 30, 2026, LB Pharmaceuticals Inc had total assets of $453.4 million and total liabilities of $35.7 million. Total assets were up 41.3% from a year earlier. Stockholders' equity was $417.6 million. It held $403.8 million in cash and investments against $5.2 million of total debt, net cash of $398.6 million. The current ratio, current assets divided by current liabilities, was 14.78.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Assets
Cash
215
-20.3%
283
321
250
270
Short-term investments
189
+321.8%
45
45
45
45
Cash and investments
404
+28.4%
328
366
295
314
Total current assets
447
+41.3%
355
389
308
316
Property and equipment, net
2
+31.5%
2
2
2
2
Total assets
453
+41.3%
362
393
313
321
Liabilities and equity
Accounts payable
7
+165.8%
3
7
2
3
Total current liabilities
30
+355.1%
24
11
7
7
Total liabilities
36
+239.5%
29
15
12
11
Stockholders' equity
418
+34.6%
332
379
301
310
Debt
Lease liabilities
5
+40.7%
5
3
4
4
Total debt
5
+40.7%
5
3
4
4
Net cash
399
+28.2%
323
362
292
311
Ratios
Current ratio
14.78x
15.08x
35.68x
41.44x
47.60x
Debt to equity
0.01x
0.02x
0.01x
0.01x
0.01x
Return on equity
-33.81%
—
—
-8.37%
—
Return on assets
-31.14%
—
—
-8.05%
—
Book value per share
12.94
11.59
13.21
11.91
12.26
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
LBRX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
, Emerging growth company
SEC CIK
1691082
Former names
LB PHARMACEUTICALS INC. (until Dec 12, 2018)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.